Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
509
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Glucose Transporters01:27

Glucose Transporters

27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disrupting pegRNA intramolecular complementarity via PBS and spacer sequence alterations can enhance prime editing efficiency.

Nucleic acids research·2026
Same author

Targeting Oxidative Stress and Mitochondrial Dysfunction in Diabetic Neuropathy: Mechanisms and Therapeutic Opportunities.

Antioxidants (Basel, Switzerland)·2026
Same author

Diagnostic and Therapeutic Challenges of Homozygous and Severe Heterozygous Familial Hypercholesterolemia from Clinical Aspect-A Single-Center Study.

Journal of clinical medicine·2025
Same author

Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes.

International journal of molecular sciences·2025
Same author

Association rule mining of time-based patterns in diabetes-related comorbidities on imbalanced data: a pre- and post-diagnosis study.

BMC medical informatics and decision making·2025
Same author

Assessment of Serum Endocan Levels and Their Associations with Arterial Stiffness Parameters in Young Patients with Systemic Lupus Erythematosus.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Jan 10, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.3K

Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction.

Nóra Homoródi1, Éva Varga2, Zoltán Szabó3

  • 1Department of Cardiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Biomedicines
|November 27, 2025
PubMed
Summary

Novel antidiabetic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors, offer cardiovascular benefits. This review compares their mechanisms, efficacy, and safety to guide clinical decisions for type 2 diabetes mellitus management.

Keywords:
adverse effectsatherosclerosiscardiovascular diseasesglucagon-like peptide-1 receptor inhibitorspersonalized treatmentsodium–glucose transport protein 2 inhibitorstherapeutic inertiatype 2 diabetes mellitus

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

589

Related Experiment Videos

Last Updated: Jan 10, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.3K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

589

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Recent advancements in antidiabetic medications have significantly impacted type 2 diabetes mellitus (T2DM) treatment and cardiovascular (CV) risk reduction strategies.
  • Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors are key novel drug classes with demonstrated CV benefits.

Purpose of the Study:

  • To provide a comparative, literature-based summary of GLP-1 receptor agonists and SGLT2 inhibitors.
  • To elucidate their mechanisms of action, CV risk reduction efficacy, and safety profiles.
  • To identify factors influencing clinical decision-making regarding their use in T2DM patients.

Main Methods:

  • Comprehensive literature review of studies on GLP-1 receptor agonists and SGLT2 inhibitors.
  • Comparative analysis of their pharmacological actions and clinical outcomes.
  • Synthesis of safety data and adverse effect profiles.

Main Results:

  • GLP-1 receptor agonists exert anti-atherosclerotic effects via improved endothelial function, reduced inflammation, and plaque stabilization.
  • SGLT2 inhibitors offer CV protection through mechanisms including natriuresis, reduced plasma volume, and enhanced ketone body utilization.
  • Both drug classes present distinct yet significant cardiovascular advantages, with specific considerations for adverse effects and potential combination therapy.

Conclusions:

  • GLP-1 receptor agonists and SGLT2 inhibitors represent distinct therapeutic avenues for managing T2DM and reducing cardiovascular risk.
  • Understanding their individual mechanisms, efficacy, and safety profiles is crucial for optimizing patient care and guiding drug selection.
  • Further research is warranted to explore optimal combination strategies and refine clinical decision-making algorithms.